A framework for the investigation of rare genetic disorders in neuropsychiatry.
Stephan J SandersMustafa SahinJoseph HostykAudrey ThurmSebastien JacquemontPaul AvillachElise DouardChrista L MartinMeera E ModiAndrés Moreno De LucaArmin RaznahanAlan AnticevicRicardo DolmetschGuoping FengDaniel H GeschwindDavid C GlahnDavid B GoldsteinDavid H LedbetterJennifer G MulleSergiu P PașcaRodney C SamacoJonathan SebatAnne PariserThomas LehnerRaquel E GurCarrie E BeardenPublished in: Nature medicine (2019)
De novo and inherited rare genetic disorders (RGDs) are a major cause of human morbidity, frequently involving neuropsychiatric symptoms. Recent advances in genomic technologies and data sharing have revolutionized the identification and diagnosis of RGDs, presenting an opportunity to elucidate the mechanisms underlying neuropsychiatric disorders by investigating the pathophysiology of high-penetrance genetic risk factors. Here we seek out the best path forward for achieving these goals. We think future research will require consistent approaches across multiple RGDs and developmental stages, involving both the characterization of shared neuropsychiatric dimensions in humans and the identification of neurobiological commonalities in model systems. A coordinated and concerted effort across patients, families, researchers, clinicians and institutions, including rapid and broad sharing of data, is now needed to translate these discoveries into urgently needed therapies.
Keyphrases
- copy number
- genome wide
- risk factors
- end stage renal disease
- electronic health record
- endothelial cells
- ejection fraction
- health information
- newly diagnosed
- social media
- big data
- prognostic factors
- palliative care
- dna methylation
- healthcare
- physical activity
- case report
- patient reported outcomes
- sleep quality
- pluripotent stem cells
- depressive symptoms
- induced pluripotent stem cells
- artificial intelligence